Enterprise Solutions Webinars

  1. Case Study: Purification Solutions For Resilience CDMO 3/31/2025

    Ensuring consistent, high-quality biopharmaceutical production hinges on dependable partnerships. Explore how a collaboration addressed supply chain vulnerabilities, facilitating rapid access to advanced resin technology.

  2. 10 Minutes On Optimizing Upstream Process Development 3/25/2025

    Gain insight into how UPD ensures scalable and compliant processes, facilitates the efficient development of innovative therapeutics, and contributes to molecule development and production.

  3. From Bench To 20k L Bioreactor: Optimizing Cell Culture Scale-Up 3/25/2025

    Master scale-up strategies, optimize key parameters, and ensure a seamless transition from bench to large-scale bioreactors for a thriving biopharmaceutical process.

  4. GMP-Focused Platform Processes For Microbial, pDNA, And mRNA 3/25/2025

    Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, explains how platform processes optimize microbial, plasmid DNA, and mRNA production.

  5. A Friendly CDMO Expert: New CEO Outlines AGC Bio's Transformation 3/25/2025

    Experience a friendlier, more reliable approach to biopharmaceutical manufacturing with AGC Biologics, your trusted partner for minimizing risks and fostering collaboration.

  6. New Protein A Device Set To Redefine Biomanufacturing 3/25/2025

    Discover how the Gore Protein A Membrane Device, in collaboration with AGC Biologics, can revolutionize your manufacturing processes, enhancing efficiency, scalability, and innovation from discovery to GMP-level production.

  7. Bora Pharmaceuticals: A Future Focused CDMO 3/25/2025

    Specializing in formulation development, clinical and commercial manufacturing, and advanced packaging solutions, we bring expertise across a diverse range of dosage forms.

  8. MilliporeSigma Bio-Expo Live February 2025: Downstream Bioprocessing 3/17/2025

    Advancements in single-use technologies are transforming antibody-drug conjugate manufacturing and offering increased flexibility. Examine key data, design considerations, operational benefits, and applications in ADC production.

  9. How Landmark Bio's Industry Partnerships Are Improving Manufacturing And Development 3/5/2025

    CEO Ran Zheng explains how industry partnerships can bring cell and gene therapies to market more efficiently and reach more patients.

  10. How Is Landmark Bio Making Cell And Gene Therapies More Accessible? 3/5/2025

    CEO Ran Zheng is leveraging her biologic therapeutic development experience to help cell and gene therapy developers overcome manufacturing and distribution hurdles.